0.61

0.16% 0.0008

Applied Therapeutics Inc (APLT)

Overview News Price History Option Chain Financials Discussions Forecast

Applied Therapeutics Inc stock is traded at $0.61, with a volume of 1.06M. It is up +0.16% in the last 24 hours and down -23.92% over the past month. Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Previous Close:

$0.6092

Open:

$0.619

24h Volume:

1.06M

Relative Volume:

0.16

Market Cap:

$70.88M

Revenue:

Net Income/Loss:

$-119.76M

P/E Ratio:

-0.4519

EPS:

-1.35

Net Cash Flow:

$-55.17M

1W Performance:

+4.03%

1M Performance:

-23.92%

6M Performance:

-90.16%

1Y Performance:

-78.21%

1-Day Range:

$0.6019

$0.6598

1-Week Range:

$0.5439

$0.6598

52-Week Range:

$0.5439

$10.62

Applied Therapeutics Inc Stock (APLT) Company Profile

Name

Applied Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

212-220-9226

Address

545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY

Employee

Twitter

@Applied_Tx

Next Earnings Date

2024-11-07

Latest SEC Filings

APLT's Discussions on Twitter

Compare APLT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APLT Applied Therapeutics Inc	0.6101	70.88M	0	-119.76M	-55.17M	-1.35
VRTX Vertex Pharmaceuticals Inc	473.24	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	715.00	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	653.00	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.48	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.55	28.75B	3.30B	-501.07M	1.03B	-2.1146

Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-23-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-02-24	Downgrade	UBS	Buy → Neutral
Nov-29-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-31-24	Initiated	William Blair	Outperform
Mar-26-24	Initiated	RBC Capital Mkts	Outperform
Feb-22-24	Initiated	Leerink Partners	Outperform
Jan-04-22	Downgrade	Barclays	Overweight → Equal Weight
Aug-27-21	Downgrade	Goldman	Neutral → Sell
Jun-25-21	Resumed	Goldman	Neutral
Oct-08-20	Initiated	Truist	Buy
Apr-22-20	Initiated	Goldman	Buy
Feb-27-20	Initiated	Barclays	Overweight
Jun-10-19	Initiated	Citigroup	Buy
Jun-10-19	Initiated	Cowen	Outperform
Jun-10-19	Initiated	Robert W. Baird	Outperform

View All

Applied Therapeutics Inc Stock (APLT) Latest News

11:00 AM

INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Applied Therapeutics, Inc. (APLT)Deadline is February 18, 2025 | FinancialContent Business Page - Financial Content

11:00 AM

10:49 AM

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics - PR Newswire

10:49 AM

Feb 06, 2025

Lead Plaintiff Deadline is February 18, 2025 for Investors of Applied TherapeuticsContact Kaplan Fox - Financial Content

Feb 06, 2025